Loading company…
Momotaro-Gene develops cancer therapies combining genetic and pharmaceutical approaches.
Founded in 2007 and based in Okayama-shi, Japan, Momotaro-Gene is developing therapies that combine the REIC/Dkk-3 gene with checkpoint inhibitors and antitumor agents. Its candidates include treatments for gliomas and liver cancer. In April 2023, the company raised JPY 499.920 mn in Series D funding from Adreic Therapeutics Inc.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in